Works matching AU Gao, Quanli

Results: 57
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1897, doi. 10.1007/s00262-021-03102-3
    By:
    • Gong, Jifang;
    • Cao, Junning;
    • Zhang, Qingyuan;
    • Xu, Nong;
    • Zhao, Yanqiu;
    • Xing, Baocai;
    • Miao, Zhanhui;
    • Wu, Yilong;
    • Pan, Hongming;
    • Gao, Quanli;
    • Li, Xingya;
    • Liu, Baorui;
    • Li, Wei;
    • Pei, Zhidong;
    • Xia, Hongqiang;
    • Qi, Qinzhou;
    • Dai, Hangjun;
    • Shi, Qingmei;
    • Yang, Jianxin;
    • Li, Jin
    Publication type:
    Article
    14

    Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).

    Published in:
    Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-28408-3
    By:
    • Xu, Jianming;
    • Li, Yi;
    • Fan, Qingxia;
    • Shu, Yongqian;
    • Yang, Lei;
    • Cui, Tongjian;
    • Gu, Kangsheng;
    • Tao, Min;
    • Wang, Xiuwen;
    • Cui, Chengxu;
    • Xu, Nong;
    • Xiao, Juxiang;
    • Gao, Quanli;
    • Liu, Yunpeng;
    • Zhang, Tao;
    • Bai, Yuxian;
    • Li, Wei;
    • Zhang, Yiping;
    • Dai, Guanghai;
    • Ma, Dong
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    The Application of Nanobody in CAR-T Therapy.

    Published in:
    Biomolecules (2218-273X), 2021, v. 11, n. 2, p. 238, doi. 10.3390/biom11020238
    By:
    • Bao, Chaolemeng;
    • Gao, Quanli;
    • Li, Lin-Lin;
    • Han, Lu;
    • Zhang, Bingxiang;
    • Ding, Yijin;
    • Song, Zongpei;
    • Zhang, Ruining;
    • Zhang, Jishuai;
    • Wu, Xian-Hui
    Publication type:
    Article
    29
    30
    31
    32
    33
    34
    35

    S-15 in combination of Akt inhibitor promotes the expansion of CD45RA<sup>−</sup>CCR7<sup>+</sup> tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1<sup>+</sup>Tim-3<sup>+</sup> cells as well as regulatory T cells.

    Published in:
    Cancer Cell International, 2019, v. 19, n. 1, p. N.PAG, doi. 10.1186/s12935-019-1043-3
    By:
    • Xu, Benling;
    • Yuan, Long;
    • Chen, Guangyu;
    • Li, Tiepeng;
    • Zhou, Jinxue;
    • Zhang, Chengjuan;
    • Qin, Peng;
    • Muthana, Musleh M.;
    • Wang, Shengdian;
    • Du, Xuexiang;
    • Gao, Quanli
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial.

    Published in:
    Cancer Communications, 2024, v. 44, n. 10, p. 1214, doi. 10.1002/cac2.12604
    By:
    • Zheng, Yan;
    • Liang, Guanghui;
    • Yuan, Dongfeng;
    • Liu, Xianben;
    • Ba, Yufeng;
    • Qin, Zimin;
    • Shen, Sining;
    • Li, Zhenxuan;
    • Sun, Haibo;
    • Liu, Baoxing;
    • Gao, Quanli;
    • Li, Peng;
    • Wang, Zongfei;
    • Liu, Shilei;
    • Zhu, Jianping;
    • Wang, Haoran;
    • Ma, Haibo;
    • Liu, Zhenzhen;
    • Zhao, Fei;
    • Zhang, Jun
    Publication type:
    Article
    47
    48
    49
    50